Two studies from the Polish Melanoma Group

Prof Anna Czarnecka, a medical oncologist from the National Research Cancer Institute in Warsaw, presented two important studies from the Polish Melanoma Group at EADO 2025 in Athens.

Real-World evidence on BRAF- / MEK-inhibitors

The first study analysed real-world outcomes of the BRAF-MEK inhibitor combination encorafenib and binimetinib in nearly 250 patients across Poland. Despite the real-world population including 25% with brain metastases (a higher-risk group than in clinical trials), the treatment showed high efficacy, especially in first-line patients with ECOG 0 and normal LDH levels. Remarkably, even in third-line use, after prior BRAF-MEK and immunotherapy, patients had a median OS of six months. Additionally, more than 10 patients experienced over five years of survival, suggesting a substantial long-term benefit in select individuals.

De-escalation of immunotherapy in metastatic melanoma

The second study focused on immune therapy “drug holidays.” In a group of 220 patients who paused immunotherapy after at least six months of treatment and confirmed tumour response (not due to toxicity), the results were very positive. Median PFS has not yet been reached. Many had received at least two years of immunotherapy and remained progression-free after stopping. Upon disease progression, half of the patients responded again when re-treated with immunotherapy. This approach could reduce treatment costs, lower toxicity, and improve quality of life without compromising outcomes.

Both studies support personalised treatment strategies and more flexible approaches in melanoma care.